Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 15/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127811 | 0.95 | L3MBTL1 (0.38) | CHRM3L3MBTL1HTTCHRM2CHRM1 | |
| SCHEMBL22213482 | 0.91 | L3MBTL1 (0.35) | CHRM3L3MBTL1HTTCHRM2CHRM1 | |
| SCHEMBL18269756 | 0.82 | LMNA (0.42) | L3MBTL1HTTMAPTALDH1A1MEN1 | |
| SCHEMBL16127934 | 0.79 | SCN1A (0.40) | MEN1LMNAKMT2A | |
| SCHEMBL19712958 | 0.78 | CHRM3 (0.45) | CHRM3L3MBTL1HTTCHRM2CHRM1 | |
| SCHEMBL20885165 | 0.78 | MTNR1A (0.33) | KMT2A | |
| SCHEMBL22213477 | 0.77 | CHRM3 (0.35) | CHRM3L3MBTL1HTTCHRM2CHRM1 | |
| SCHEMBL17036157 | 0.74 | LMNA (0.38) | L3MBTL1MAPTALDH1A1MEN1LMNA | |
| SCHEMBL16143851 | 0.73 | CHRNB2 (0.43) | L3MBTL1HTTMAPTALDH1A1LMNA | |
| SCHEMBL12018024 | 0.73 | CHRNB2 (0.49) | L3MBTL1ALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9730864-B2 | Addition-fragmentation oligomers having high refractive index groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160346170-A1 | ADDITION-FRAGMENTATION OLIGOMERS HAVING HIGH REFRACTIVE INDEX GROUPS | 3M INNOVATIVE PROPERTIES COMPANY | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346170-A1 | ADDITION-FRAGMENTATION OLIGOMERS HAVING HIGH REFRACTIVE INDEX GROUPS | ZYX, MACF1, PYCARD | CHRM3 3602/4885L3MBTL1 2887/4885HTT 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.